Resurrect Bio is an agricultural biotech developing gene-edited disease resistance by reactivating cryptic resistance genes already latent in elite crop germplasm, rather than inserting foreign DNA. Three stacked platforms drive the work: FloraFold AI, an in-silico discovery engine that predicts plant-pathogen protein interactions; a high-throughput functional biology platform that validates those predictions in living plants; and the Resurrection platform that reactivates the dormant resistance mechanisms. The company claims trait discovery up to five times faster than traditional methods, with traits containing as few as one DNA change, which also carries regulatory advantages. It engages seed companies and breeders through joint development agreements and spun out of The Sainsbury Laboratory in Norwich.
Funding
Resurrect Bio closed an oversubscribed $10.3 million Series A announced in May 2026, led by Corteva via Corteva Catalyst, with Calculus Capital, Pymwymic, UKI2S, SynBioVen and AgFunder participating. This was the final close of a two-tranche round whose $8.1 million initial close was announced in February 2026, bringing total funding to roughly $12.4 million since founding.